乳头状甲状腺癌（PTC）颈部淋巴结转移（CLNM）增加肿瘤复发率并降低患者长期生存率。目前纳米炭（CNP）示踪颈部淋巴结在术中起关键作用，但常伴假阳性和假阴性，因此精准识别和定位清扫CLNM仍是根治PTC亟待解决的难题。我们前期研究发现177Lu-CNP能在体外靶向PTC，据此拟用对肿瘤新生血管整合素受体具有特异性靶向的环状多肽iRGD，设计新颖的177Lu-CNP-iRGD双靶向纳米探针，利用iRGD和CNP双重靶向PTC及CLNM，再结合177Lu诊疗一体化特征，进行体内外实验。通过Radio-HPLC、结合及阻断试验、SPECT/CT显像、PRRT处理等技术，评估探针特异稳定性及靶向性；通过生物分布、组织形态、缩瘤率、αvβ3及TG表达，验证探针可精准识别CLNM，并可针对肿瘤组织进行辐射损伤诱发细胞凋亡坏死达到诊断、治疗的目的，为丰富PTC及CLNM诊治策略提供新的科学方法和思路。

Cervical lymph node metastasis (CLNM) is commonly observed in papillary thyroid carcinoma (PTC), which might be associated with increased risk of regional recurrence and reduced rate of long-term survival. Until now, although the application of carbon nanoparticles (CNP) probes to trace cervical lymph nodes plays a vital role in guiding surgery, it was always accompanied with both false positives and false negative results. Therefore, how to establish an accurate identification and localization CLNM method in PTC is urgently needed. Our pre-study had shown high-binding-ability of 177Lu-CNP in vitro to PTC tumor cells. Therefore, based on the circular peptide iRGD that specifically targets the tumor neovascularization integrin receptor and CNP nanoparticle, and we design a novel CNP-iRGD dual-targeting multimodal nanoprobe. And then label the probe with 177Lu for both of diagnosis and therapy and.perform the in vitro and in vivo experiments. Such as the HPLC analysis, binding and blocking assays, SPECT/CT imaging, PRRT processing techniques to evaluate the specific stability and targeting. Through biodistribution, histomorphology, shrinkage rate, αvβ3 and TG protein expression, we expect to verify that the probe can accurately identify CLNM. In addition, radiation damage can induce apoptosis and necrosis of tumor tissue. Therefor we can provide a new method for the diagnosis and therapy of CLNM.